From NASDAQ.: 2025-04-24 19:03:00

NovoCure (NASDAQ: NVCR) reported strong quarterly results for the first quarter of 2025, with net revenue of nearly $155 million, a 12% improvement from 2024, and a narrowed GAAP net loss of $34.4 million. The stock price rose over 4% in response, outperforming the S&P 500. Analysts were pleasantly surprised by the company’s performance, as their estimates were lower. NovoCure’s unique technology, tumor treating fields (TTFs), is gaining attention for its potential to treat cancers with fewer side effects. The company is also expanding into new areas, making it a stock to watch for potential growth.



Read more at NASDAQ.: Why NovoCure Stock Leaped 4% Higher Today